COLOSSUS involves 14 different partners from 8 different countries. The Project brings together a multi-disciplinary team with expertise including cancer immunology, systems biology, computational modelling, bioinformatics, omics analysis, clinical oncology/pathology, preclinical research/imaging, clinical trials, health economics and patient engagement.
Prof Annette Byrne (RCSI) is the Coordinator of COLOSSUS
Prof Annette Byrne (RCSI)
Prof Byrne is Associate Professor, (Physiology), Head of the Laboratory of Tumour Biology and Molecular Imaging at RCSI and Principal Investigator (PI) in the RCSI Dept of Physiology and Medical Physics and Centre for Systems Medicine. Prof Byrne has more than 18 years experience in tumor biology and biomarker/drug discovery in oncology, gained through time spent in the US biotech/pharma sector and in academia. She successfully co-ordinated the €6M FP7 project ANGIOPREDICT and the FP7 Marie Curie Industry Academia Pathways and Partnerships Programme (IAPP) project AngioTox. Prof. Byrne received an EU ‘Champion of Research’ award from Michael D. Higgins, President of Ireland in June 2012 and received the award again in 2017. She has published in leading Cancer Journals including Nature Reviews Cancer, Cancer Research, Clinical Cancer Research and Cancer Discovery.
The Scientific Leads
Prof Byrne (see above), Prof Jochen Prehn (RCSI) and Dr Rodrigo Dienstmann (VHIO) comprise the Scientific Leads.
Prof Jochen Prehn
Prof Jochen Prehn is the Director of the RCSI Centre of Systems Medicine and Chair of the RCSI Dept of Physiology and Medical Physics. Prof Prehn has acted as coordinator and/or Principal Investigator for a number of national and international research projects including APO-DECIDE, OXYSENSE and APO-SYS. Prof Prehn is an expert in medical systems biology and cell survival and death signalling and has 157 peer-reviewed publications including publications in Mol Syst Biol, Nature Genetics, Cancer Research, Proc Natl Acad Sci USA, EMBO J and J Cell Biol (h-index 44; >6,500 cited publications).
Dr Rodrigo Dienstmann
Dr Rodrigo Dienstmann, M.D. is a medical oncologist with expertise in clinical and translational research. He is Principal Investigator of the Oncology Data Science Group of Vall d’Hebron Institute of Oncology, integrating clinical and translational research with genomics for precision cancer therapy. Dr Dienstmann was deeply involved in the Colorectal Cancer Subtyping Consortium, which resulted in the identification and clinical-molecular characterization of the intrinsic disease subtypes.